Physician profile
Jin Zhao
NPI 1083061923
$6,781.08
in general payments reported to CMS, 2019-2025
14 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.90 · 2020: $234 · 2021: $645 · 2022: $64.39 · 2023: $2,155 · 2024: $1,379 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,494 · Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,493.87 |
| Food and Beverage | $1,329.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,631.78 | 2020-2025 | Triclip, Mitraclip |
| Heartflow, INC. | $344.96 | 2023-2025 | Ffrct |
| Tricoast Surgical Solutions LLC | $130.39 | 2024 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2022-2025 | |
| Boston Scientific Corporation | $111.51 | 2023-2025 | Watchman Access System |
| Amgen INC. | $99.86 | 2022-2024 | Repatha |
| Abiomed | $80.45 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.24 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $69.67 | 2022-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $33.92 | 2023-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $33.58 | 2023 | Xarelto |
| Vital Connect, INC | $20.82 | 2023 | Vitalpatch Rtm |
| Biotronik INC. | $15.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.